CN108290922B - 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 - Google Patents

用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 Download PDF

Info

Publication number
CN108290922B
CN108290922B CN201680067912.8A CN201680067912A CN108290922B CN 108290922 B CN108290922 B CN 108290922B CN 201680067912 A CN201680067912 A CN 201680067912A CN 108290922 B CN108290922 B CN 108290922B
Authority
CN
China
Prior art keywords
group
compound
substituted
alkoxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680067912.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108290922A (zh
Inventor
麦琳·维斯尼克
江昕
M·R·奥特玛
芝塔斯·李
B·W·卡普拉瑟
威廉·H·洛克
加里·波尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CN108290922A publication Critical patent/CN108290922A/zh
Application granted granted Critical
Publication of CN108290922B publication Critical patent/CN108290922B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201680067912.8A 2015-09-23 2016-09-23 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 Active CN108290922B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222632P 2015-09-23 2015-09-23
US62/222,632 2015-09-23
PCT/US2016/053545 WO2017053868A1 (en) 2015-09-23 2016-09-23 C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses

Publications (2)

Publication Number Publication Date
CN108290922A CN108290922A (zh) 2018-07-17
CN108290922B true CN108290922B (zh) 2021-12-07

Family

ID=57137257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680067912.8A Active CN108290922B (zh) 2015-09-23 2016-09-23 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物

Country Status (14)

Country Link
US (2) US11584775B2 (enExample)
EP (1) EP3353190B1 (enExample)
JP (1) JP7074674B2 (enExample)
KR (1) KR102796889B1 (enExample)
CN (1) CN108290922B (enExample)
AU (1) AU2016326704B2 (enExample)
BR (1) BR112018005861B1 (enExample)
CA (1) CA2998681C (enExample)
EA (1) EA201890767A1 (enExample)
ES (1) ES2865163T3 (enExample)
IL (1) IL258185B (enExample)
MX (1) MX386256B (enExample)
NZ (1) NZ741082A (enExample)
WO (1) WO2017053868A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
TW201348245A (zh) 2012-04-27 2013-12-01 Reata Pharmaceuticals Inc 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２－二氟基丙醯胺衍生物、多晶型及其使用方法
MX366913B (es) 2012-09-10 2019-07-30 Reata Pharmaceuticals Inc Derivados de c17-alcanodiilo y alquenodiilo de ácido oleanólico y métodos de uso de los mismos.
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
CN108299541B (zh) * 2018-01-18 2020-12-11 华南师范大学 海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与抗炎应用
CN108191944B (zh) * 2018-01-18 2020-12-11 华南师范大学 海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与糖酶应用
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CN109248168A (zh) * 2018-10-30 2019-01-22 武汉卫无忧生物科技有限公司 齐墩果酸在制备抗幽门螺杆菌的药物中的用途
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
TWI861163B (zh) * 2019-07-19 2024-11-11 美商瑞塔醫藥有限責任公司 C17經極性取代之雜芳合成三萜類化合物及其使用方法
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
JP2024504637A (ja) * 2021-01-18 2024-02-01 リアタ ファーマシューティカルズ インコーポレイテッド 合成ウルソール酸誘導体及びその使用方法
CN113185570A (zh) * 2021-05-12 2021-07-30 张洪胜 一种治疗银屑病的齐墩果酸衍生物及其制备方法
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184578A1 (en) * 2011-01-14 2012-07-19 Heptiva LLC Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
CN103665087A (zh) * 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE19817262A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
ATE449754T1 (de) 1999-05-14 2009-12-15 Nereus Pharmaceuticals Inc Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US20040234977A1 (en) 2001-05-14 2004-11-25 Da-Wei Gong Novel alanine transaminase enzyme and methods of use
DK1465615T3 (da) 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DE60325329D1 (de) 2002-01-18 2009-01-29 Univ Minnesota Quaternäre terpensalze als biologisch aktive tenside
JP2006515859A (ja) 2002-05-13 2006-06-08 トラスティーズ オブ ダートマス カレッジ 阻害剤およびその使用法
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
WO2006029221A2 (en) 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
JP2009530405A (ja) 2006-03-23 2009-08-27 アドバンスト ライフ サイエンシズ インコーポレイテッド 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008000068A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
ES2916604T1 (es) 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
US8129429B2 (en) 2008-01-11 2012-03-06 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
NZ588711A (en) 2008-04-18 2012-10-26 Reata Pharmaceuticals Inc C-17 homologated oleanolic acid derivatives for treating cancer
CN101298466B (zh) 2008-06-13 2014-04-09 南京大学 齐墩果酸衍生物及其制备方法和应用
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
LT3254675T (lt) 2009-02-13 2019-06-25 Reata Pharmaceuticals, Inc. Sulėtinto atpalaidavimo peroralinio vartojimo kompozicijos, kurių sudėtyje yra amorfinis cddo-me
LT2558105T (lt) 2010-04-12 2020-02-10 Reata Pharmaceuticals, Inc. Bardoksolono metilas, skirtas nutukimo gydymui
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
EP2683731B1 (en) * 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
US8987502B2 (en) 2011-12-01 2015-03-24 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof
TW201348245A (zh) 2012-04-27 2013-12-01 Reata Pharmaceuticals Inc 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２－二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
SMT201700501T1 (it) 2012-09-10 2017-11-15 Reata Pharmaceuticals Inc Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MX366913B (es) 2012-09-10 2019-07-30 Reata Pharmaceuticals Inc Derivados de c17-alcanodiilo y alquenodiilo de ácido oleanólico y métodos de uso de los mismos.
MY198522A (en) 2013-08-23 2023-09-04 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CN104861027A (zh) 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型齐墩果酸衍生物、其制备方法及其应用
US9896475B2 (en) 2014-08-26 2018-02-20 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184578A1 (en) * 2011-01-14 2012-07-19 Heptiva LLC Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
CN103665087A (zh) * 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice;Leo R. Fitzpatrick et al.;《Inflammopharmacol》;20140409;第22卷;第341-349页 *
The Synthetic Triterpenoid, CDDO-Me, Modulates the Proinfl ammatory Response to In Vivo Lipopolysaccharide Challenge;Jeffery J. Auletta et al.;《Journal of Interferon & Cytokine Research》;20101231;第30卷(第7期);第497-508页 *
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis;Tej K. Pareek et al.;《Scientific Reports》;20111219;第1卷;第201页 *

Also Published As

Publication number Publication date
AU2016326704A1 (en) 2018-04-26
JP2018528275A (ja) 2018-09-27
WO2017053868A1 (en) 2017-03-30
IL258185B (en) 2021-08-31
US20190153022A1 (en) 2019-05-23
AU2016326704B2 (en) 2021-01-28
CA2998681A1 (en) 2017-03-30
ES2865163T3 (es) 2021-10-15
WO2017053868A8 (en) 2018-04-19
JP7074674B2 (ja) 2022-05-24
IL258185A (en) 2018-05-31
EP3353190A1 (en) 2018-08-01
KR102796889B1 (ko) 2025-04-17
KR20180061251A (ko) 2018-06-07
CA2998681C (en) 2024-02-06
MX386256B (es) 2025-03-18
BR112018005861B1 (pt) 2022-11-22
MX2018003569A (es) 2018-11-29
US11584775B2 (en) 2023-02-21
CN108290922A (zh) 2018-07-17
HK1258095A1 (zh) 2019-11-01
US20230250130A1 (en) 2023-08-10
NZ741082A (en) 2023-06-30
BR112018005861A2 (pt) 2018-10-16
EP3353190B1 (en) 2021-03-17
EA201890767A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
CN108290922B (zh) 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物
CN103619866B (zh) C4-一甲基三萜系化合物的衍生物及其使用方法
CN107428698B (zh) 作为抗氧化炎症调节剂的咪唑基三环烯酮
BR112013015241B1 (pt) Compostos de enonas tricíclicas de pirazolila e pirimidinila e composição farmacêutica
KR20180133461A (ko) 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
JP2024517906A (ja) スルホンイミドイル含有ａｔｒ阻害剤化合物
FR3021318A1 (fr) Produits derives de la 20-hydroxyecdysone et leur utilisation dans la preparation de medicaments
TW201827406A (zh) Ｎｒｆ２活化劑
CN105399698B (zh) 芳杂环类衍生物及其在药物中的应用
HK1258095B (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
CN117015548A (zh) 合成的熊果酸衍生物和其使用方法
EA041119B1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и содержащие их фармацевтические композиции
HK1247609A1 (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
US20250270209A1 (en) Lrrk2 inhibitors
HK1247609B (zh) 作为抗氧化炎症调节剂的咪唑基三环烯酮
HK40080975A (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
HK40073498B (zh) C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
HK1189894A (en) C4-monomethyl triterpenoid derivatives and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258095

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant